Cite
MLA Citation
D. Sermer et al.. “SAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMAB (PEM) AND ENTINOSTAT (ENT) IN RELAPSED AND REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND FOLLICULAR LYMPHOMA (FL).” Hematological oncology, vol. 37, n.d., pp. 331–332. http://access.bl.uk/ark:/81055/vdc_100086191599.0x00004c